NO2419104T3 - - Google Patents

Info

Publication number
NO2419104T3
NO2419104T3 NO10713790A NO10713790A NO2419104T3 NO 2419104 T3 NO2419104 T3 NO 2419104T3 NO 10713790 A NO10713790 A NO 10713790A NO 10713790 A NO10713790 A NO 10713790A NO 2419104 T3 NO2419104 T3 NO 2419104T3
Authority
NO
Norway
Application number
NO10713790A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2419104T3 publication Critical patent/NO2419104T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO10713790A 2009-04-13 2010-04-12 NO2419104T3 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
NO2419104T3 true NO2419104T3 (lt) 2018-04-07

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10713790A NO2419104T3 (lt) 2009-04-13 2010-04-12

Country Status (23)

Country Link
US (2) US8404711B2 (lt)
EP (1) EP2419104B1 (lt)
JP (1) JP2012523437A (lt)
KR (1) KR20120017421A (lt)
CN (2) CN105832735A (lt)
AU (1) AU2010236734B2 (lt)
BR (1) BRPI1013777A8 (lt)
CA (1) CA2758321A1 (lt)
CY (1) CY1119800T1 (lt)
DK (1) DK2419104T3 (lt)
ES (1) ES2654930T3 (lt)
HR (1) HRP20180018T1 (lt)
HU (1) HUE038141T2 (lt)
IL (1) IL215660A0 (lt)
LT (1) LT2419104T (lt)
MX (1) MX2011010782A (lt)
NO (1) NO2419104T3 (lt)
PL (1) PL2419104T3 (lt)
PT (1) PT2419104T (lt)
RU (1) RU2569056C2 (lt)
SI (1) SI2419104T1 (lt)
WO (1) WO2010120695A2 (lt)
ZA (1) ZA201107490B (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DK2540297T3 (en) 2008-11-19 2015-07-13 Forum Pharmaceuticals Inc The treatment of cognitive disorders with (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CA2761716A1 (en) * 2009-05-11 2010-11-18 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
SI3029039T1 (en) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
KR101476236B1 (ko) 2012-08-16 2014-12-24 경희대학교 산학협력단 노화 및 치매의 예방 및/또는 치료 활성을 갖는 유산균
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
KR102676011B1 (ko) 2017-05-24 2024-06-17 하. 룬드벡 아크티에셀스카브 Apoe4 대립형질을 보유하는 환자 하위집단에서 알츠하이머병의 치료에 사용하기 위한 5-ht6 수용체 길항제 및 아세틸콜린에스테라제 억제제의 조합
EP3630113A4 (en) 2017-06-01 2021-02-24 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION, INCLUDING PDE9 INHIBITOR
CN116473962A (zh) 2017-06-02 2023-07-25 富士胶片富山化学株式会社 脑萎缩预防或治疗剂
JP7431721B2 (ja) 2017-07-31 2024-02-15 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ベルセトラグを用いて胃不全麻痺の症状を治療する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124730T2 (de) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
LT2419104T (lt) 2018-02-12
CY1119800T1 (el) 2018-06-27
CN105832735A (zh) 2016-08-10
JP2012523437A (ja) 2012-10-04
HRP20180018T1 (hr) 2018-02-09
SI2419104T1 (en) 2018-03-30
EP2419104A2 (en) 2012-02-22
WO2010120695A2 (en) 2010-10-21
RU2569056C2 (ru) 2015-11-20
KR20120017421A (ko) 2012-02-28
ES2654930T3 (es) 2018-02-15
HUE038141T2 (hu) 2018-10-29
CN102395371A (zh) 2012-03-28
DK2419104T3 (en) 2018-02-05
RU2011146032A (ru) 2013-05-20
MX2011010782A (es) 2012-01-20
AU2010236734A8 (en) 2012-02-16
ZA201107490B (en) 2012-06-27
BRPI1013777A2 (pt) 2016-04-05
US8404711B2 (en) 2013-03-26
US20100261752A1 (en) 2010-10-14
WO2010120695A3 (en) 2010-12-02
PT2419104T (pt) 2018-01-31
EP2419104B1 (en) 2017-11-08
PL2419104T3 (pl) 2018-04-30
US20140057939A1 (en) 2014-02-27
AU2010236734B2 (en) 2015-06-11
AU2010236734A1 (en) 2011-11-03
IL215660A0 (en) 2012-01-31
CA2758321A1 (en) 2010-10-21
BRPI1013777A8 (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
BR112012012396A2 (lt)
BR112012008267A2 (lt)
BR112012003062A2 (lt)
BR112012000607A2 (lt)
BRPI0925311A2 (lt)
BRPI0924307A2 (lt)
BR122021004633A2 (lt)
BR112012003080A2 (lt)
BR122017024704A2 (lt)
BR112012012487A2 (lt)
BR112012000665A2 (lt)
BR112012003853A2 (lt)
BR112012012080A2 (lt)
BR112012009446A2 (lt)
BR112012009703A2 (lt)
BR112012010357A2 (lt)
BR122019005883A2 (lt)
BR112012002627A2 (lt)
BR112012001263A2 (lt)
BR112012000159A2 (lt)
BRPI0924534A2 (lt)
BR112012007654A2 (lt)
BR112012005951A2 (lt)
BR112012000255A2 (lt)
BR112012009404A2 (lt)